参考文献
2020-10-14
1: Liao C, Hsu J, Kim Y, Hu DQ, Xu D, Zhang J, Pashine A, Menke J, Whittard T,
Romero N, Truitt T, Slade M, Lukacs C, Hermann J, Zhou M, Lucas M, Narula S,
DeMartino J, Tan SL. Selective inhibition of spleen tyrosine kinase (SYK) with a
novel orally bioavailable small molecule inhibitor, RO9021, impinges on various
innate and adaptive immune responses: implications for SYK inhibitors in
autoimmune disease therapy. Arthritis Res Ther. 2013 Oct 4;15(5):R146. doi:
10.1186/ar4329. PubMed PMID: 24286216; PubMed Central PMCID: PMC3978604.
Romero N, Truitt T, Slade M, Lukacs C, Hermann J, Zhou M, Lucas M, Narula S,
DeMartino J, Tan SL. Selective inhibition of spleen tyrosine kinase (SYK) with a
novel orally bioavailable small molecule inhibitor, RO9021, impinges on various
innate and adaptive immune responses: implications for SYK inhibitors in
autoimmune disease therapy. Arthritis Res Ther. 2013 Oct 4;15(5):R146. doi:
10.1186/ar4329. PubMed PMID: 24286216; PubMed Central PMCID: PMC3978604.
